3 Regulated-Market Generics Maker, Specialty Branded Generics Seller and Large Active Ingredients Producer Stocks With a Strong Future Roadmap: Strides Pharma Science, Ajanta Pharma and Divi's Laboratories

Generic formulation and API pharma stocks give investors a way to track businesses that sit close to everyday demand in India. Strides Pharma Science, Ajanta Pharma and Divi's Laboratories cover a regulated-market generics maker, a specialty branded generics seller and a large active ingredients producer.

This list covers three generic formulation and API pharma stocks with complete current figures: Strides Pharma Science, Ajanta Pharma and Divi's Laboratories. Every figure comes from the latest reported financials and the 23 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Generic Formulation and API Pharma Stocks?

Generic formulation and API pharma stocks are listed drug makers that sell finished generics, specialty brands and active pharmaceutical ingredients to buyers in India and overseas. Their earnings depend on approvals, product mix, plant quality and export demand.

Generic Formulation and API Pharma Stocks at a Glance

On valuation, Strides Pharma Science trades at a P/E below the industry P/E, while Ajanta Pharma and Divi's Laboratories trade above it, which reflects the growth the market already expects. Readers comparing generic formulation and API pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in generic formulation and API pharma stocks can use the coming numbers to test whether growth is holding.

Why Do Generic Formulation and API Pharma Stocks Have a Strong Roadmap in India?

Generic formulation and API pharma stocks have a strong roadmap in India because global buyers keep adding Indian suppliers, and specialty brands and ingredient supply chains offer room for steady growth.

• Regulated markets. Approved plants win repeat orders from overseas buyers.
• Specialty brands. Eye, skin and heart brands earn loyal prescriptions.
• Ingredient supply. Global makers need dependable large-scale suppliers.

Why Strides Pharma Science Features Among These Generic Formulation and API Pharma Stocks

Among the generic formulation and API pharma stocks on this list, Strides Pharma Science, based in Bengaluru, makes finished dosage generics for the United States and other regulated markets, with oral solids and soft gel capsules as important product groups.

In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%.

Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0.

Roadmap: The company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.

What to watch: Track new US launches and the pace of price erosion in generic categories.

Why Ajanta Pharma Features Among These Generic Formulation and API Pharma Stocks

Among the finished dosage maker shares on this list, Ajanta Pharma is a specialty pharmaceutical company that sells branded generics in India and in emerging markets across Asia and Africa, with a focus on ophthalmology, dermatology, cardiology and pain management, and also sells generics in the United States.

The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P/E of 36.3, above the industry P/E of 36.0.

Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore.

Roadmap: The company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.

What to watch: Monitor the pace of new launches in branded markets and the recovery trends in the United States generics business.

Why Divi's Laboratories Features Among These Generic Formulation and API Pharma Stocks

Among the three companies on this list, Divi's Laboratories is a Hyderabad-based maker of active pharmaceutical ingredients, intermediates and custom synthesis products, serving large global pharma companies from large-scale manufacturing sites.

Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%. Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%.

In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P/E of 82.5, above the industry P/E of 36.0.

Roadmap: The company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.

What to watch: Check the order flow in custom synthesis and the commissioning of new capacity.

Strides Pharma Science vs Ajanta Pharma vs Divi's Laboratories on Key Financials

The table below sets the three generic formulation and API pharma stocks side by side on revenue, profit and margin, using reported figures.

Ajanta Pharma posts the highest return on equity in this group at 23.3%. Divi's Laboratories has the largest FY26 revenue at Rs 11,067 crore, and Ajanta Pharma shows the fastest revenue growth with a 12.9% compound annual rate. A useful habit with generic formulation and API pharma stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several ophthalmology and ingredient stocks instead of one name, which keeps a single result from deciding the outcome.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Generic Formulation and API Pharma Stocks

Every theme carries risks that deserve a check before any decision. For these generic formulation and API pharma stocks, the main points are: Long-term finished dosage maker shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulatory checks. Plant inspections can affect approvals and shipments.
• Price pressure. Generic prices abroad can fall.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter generic formulation and API pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Generic Formulation and API Pharma Stocks

Generic formulation and API pharma stocks work best when investors track growth, valuation and return on equity side by side. Strides Pharma Science, Ajanta Pharma and Divi's Laboratories each have a clear plan to widen their reach. Based on the 23 October 2026 close, Strides Pharma Science trades at Rs 1,014.8, Ajanta Pharma at Rs 3,283.9 and Divi's Laboratories at Rs 8,950. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these generic formulation and API pharma stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track generic formulation and API pharma stocks, set price alerts and get research-backed stock ideas.

What are generic formulation and API pharma stocks?

Ans. Generic formulation and API pharma stocks are listed drug makers that sell finished generics, specialty brands and active pharmaceutical ingredients to buyers in India and overseas. Their earnings depend on approvals, product mix, plant quality and export demand. This list looks at three of them, Strides Pharma Science, Ajanta Pharma and Divi's Laboratories, using reported FY22 to FY26 financials and the 23 October 2026 closing prices.

Which generic formulation and API pharma stocks are covered in this list?

Ans. This list covers Strides Pharma Science, Ajanta Pharma and Divi's Laboratories. Based on the 23 October 2026 close, Strides Pharma Science traded at Rs 1,014.8, Ajanta Pharma at Rs 3,283.9 and Divi's Laboratories at Rs 8,950. Their return on equity ranges from 15.3% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.1% to 12.9%.

Why do generic formulation and API pharma stocks have a strong future roadmap in India?

Ans. Generic formulation and API pharma stocks have a strong roadmap in India because global buyers keep adding Indian suppliers, and specialty brands and ingredient supply chains offer room for steady growth. The main drivers are as follows. Regulated markets. Approved plants win repeat orders from overseas buyers. Specialty brands. Eye, skin and heart brands earn loyal prescriptions. Ingredient supply. Global makers need dependable large-scale suppliers. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Strides Pharma Science performed financially?

Ans. Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0. Looking ahead, the company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.

How has Ajanta Pharma performed financially?

Ans. Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P/E of 36.3, above the industry P/E of 36.0. Looking ahead, the company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.

How has Divi's Laboratories performed financially?

Ans. Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%. Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P/E of 82.5, above the industry P/E of 36.0. Looking ahead, the company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.

What risks should investors check before buying generic formulation and API pharma stocks?

Ans. Investors should check a few risks before buying generic formulation and API pharma stocks. Regulatory checks. Plant inspections can affect approvals and shipments. Price pressure. Generic prices abroad can fall. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of generic formulation and API pharma stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 23 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.